BotswanaTuberculosis profile
Population  2015 2.3 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.59 (0.35–0.9) 26 (15–40)
Mortality (HIV+TB only) 1.4 (0.67–2.5) 63 (30–110)
Incidence  (includes HIV+TB) 8 (5.2–11) 356 (230–508)
Incidence (HIV+TB only) 4.8 (3.1–6.9) 213 (136–306)
Incidence (MDR/RR-TB)** 0.47 (0.3–0.63) 21 (13–28)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.32 (0.16–0.48) 3.2 (1.7–4.7) 3.5 (1.9–5.1)
Males 0.3 (0.19–0.42) 4.2 (3–5.5) 4.5 (3.1–5.9)
Total 0.62 (0.42–0.82) 7.4 (5.7–9.1) 8 (5.2–11)
TB case notifications, 2015  
Total cases notified 5 073
Total new and relapse 4 972
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 91%
          - % pulmonary 81%
          - % bacteriologically confirmed among pulmonary 52%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 62% (43–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.26 (0.13–0.46)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 2 693 60%
          - on antiretroviral therapy 2 099 78%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  220
(160–280)
Estimated % of TB cases with MDR/RR-TB 3.6% (2.4–4.8) 13% (7.4–19)  
% notified tested for rifampicin resistance <1% 3% 61
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 57, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 61, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 77% 6 439
Previously treated cases, excluding relapse, registered in 2014 57% 103
HIV-positive TB cases, all types, registered in 2014 77% 3 537
MDR/RR-TB cases started on second-line treatment in 2013 71% 102
XDR-TB cases started on second-line treatment in 2013 50% 2
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 36
Funding source: 72% domestic, 28% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data